These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

323 related articles for article (PubMed ID: 2575762)

  • 1. In vitro pharmacologic profile of the novel beta-adrenoceptor antagonist and vasodilator, carvedilol.
    Nichols AJ; Sulpizio AC; Ashton DJ; Hieble JP; Ruffolo RR
    Pharmacology; 1989; 39(5):327-36. PubMed ID: 2575762
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The interaction of the enantiomers of carvedilol with alpha 1- and beta 1-adrenoceptors.
    Nichols AJ; Sulpizio AC; Ashton DJ; Hieble JP; Ruffolo RR
    Chirality; 1989; 1(4):265-70. PubMed ID: 2577144
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Studies on the mechanism of arterial vasodilation produced by the novel antihypertensive agent, carvedilol.
    Nichols AJ; Gellai M; Ruffolo RR
    Fundam Clin Pharmacol; 1991; 5(1):25-38. PubMed ID: 1712335
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vanidilol: a vanilloid-type vasorelaxant and ocular hypotensive beta-adrenoceptor blocker with partial beta-2-agonist activity.
    Sheu MM; Wu BN; Ho WC; Hong SJ; Chen SJ; Lin YT; Chen IJ
    Pharmacology; 1997 Apr; 54(4):211-24. PubMed ID: 9211567
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vascular effects of carvedilol, a new beta-adrenoceptor antagonist with vasodilating properties, in isolated canine coronary artery.
    Hattori Y; Nakaya H; Endou M; Nakao Y; Kanno M
    J Cardiovasc Pharmacol; 1989 Apr; 13(4):572-9. PubMed ID: 2470994
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adrenoceptor-blocking activity and cardiohemodynamic effects of carvedilol in animals.
    Kawada T; Ishibashi T; Nakazawa M; Satoh S; Imai S
    J Cardiovasc Pharmacol; 1990 Jul; 16(1):147-53. PubMed ID: 1696657
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Carvedilol blockade of rat myocardial alpha1-adrenoceptors.
    Qvigstad E; Osnes JB; Sandnes D; Schiander I; Bøkenes J; Sjaastad I; Skomedal T
    Eur J Pharmacol; 2003 Nov; 481(1):83-9. PubMed ID: 14637179
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vanidipinedilol: a vanilloid-based beta-adrenoceptor blocker displaying calcium entry blocking and vasorelaxant activities.
    Yeh JL; Liou SF; Liang JC; Huang YC; Chiang LC; Wu JR; Lin YT; Chen IJ
    J Cardiovasc Pharmacol; 2000 Jan; 35(1):51-63. PubMed ID: 10630733
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The pharmacology of carvedilol.
    Ruffolo RR; Gellai M; Hieble JP; Willette RN; Nichols AJ
    Eur J Clin Pharmacol; 1990; 38 Suppl 2():S82-8. PubMed ID: 1974511
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative analysis of beta-1 adrenoceptor agonist and antagonist potency and selectivity of cicloprolol, xamoterol and pindolol.
    Hicks PE; Cavero I; Manoury P; Lefevre-Borg F; Langer SZ
    J Pharmacol Exp Ther; 1987 Sep; 242(3):1025-34. PubMed ID: 2888869
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Carvedilol blockade of alpha1- and beta-adrenoceptor induced inotropic responses in rats with congestive heart failure.
    Qvigstad E; Sjaastad I; Bøkenes J; Schiander I; Solberg L; Sejersted OM; Osnes JB; Skomedal T
    Eur J Pharmacol; 2005 May; 516(1):51-9. PubMed ID: 15916756
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Myocardial protection by the novel vasodilating beta-blocker, carvedilol: potential relevance of anti-oxidant activity.
    Feuerstein GZ; Yue TL; Cheng HY; Ruffolo RR
    J Hypertens Suppl; 1993 Jun; 11(4):S41-8. PubMed ID: 8104241
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-hypertension effect of vanylidilol: a phenylaldehyde alpha/beta-adrenoceptor blocker with endothelium-dependent and K+ channels opening-associated vasorelaxant activities.
    Chiu CC; Wu JR; Lee CH; Liou SF; Dai ZK; Chen IJ; Yeh JL
    Pharmacology; 2004 Mar; 70(3):140-51. PubMed ID: 14752234
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alpha and beta adrenoceptor blocking action of carvedilol in the canine mesenteric artery and vein.
    Seki N; Nagao T; Komori K; Suzuki H
    J Pharmacol Exp Ther; 1988 Sep; 246(3):1116-22. PubMed ID: 2901485
    [TBL] [Abstract][Full Text] [Related]  

  • 15. General pharmacological profiles of the new beta-adrenoceptor antagonist carvedilol.
    Hirohashi M; Takasuna K; Tamura K; Yamaguchi K; Maekawa K; Yamada S; Iwasaki S; Yoshida M; Nomura M; Taguchi K
    Arzneimittelforschung; 1990 Jul; 40(7):735-46. PubMed ID: 1977393
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-thrombotic effects of nebivolol and carvedilol: Involvement of β2 receptors and COX-2/PGI2 pathways.
    Kozlovski VI; Lomnicka M; Bartus M; Sternak M; Chlopicki S
    Pharmacol Rep; 2015 Oct; 67(5):1041-7. PubMed ID: 26398401
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro characterization of the adrenoceptor activity of AY-28,925.
    Rimele TJ; Heaslip RJ; Lee DK; Grimes D
    J Pharmacol Exp Ther; 1986 Oct; 239(1):1-8. PubMed ID: 2876089
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacodynamic profile of carvedilol.
    van Zwieten PA
    Cardiology; 1993; 82 Suppl 3():19-23. PubMed ID: 8106159
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacological characteristics of the stereoisomers of carvedilol.
    Bartsch W; Sponer G; Strein K; Müller-Beckmann B; Kling L; Böhm E; Martin U; Borbe HO
    Eur J Clin Pharmacol; 1990; 38 Suppl 2():S104-7. PubMed ID: 1974497
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vasomolol: an ultra short-acting and vasorelaxant vanilloid type beta 1-adrenoceptor antagonist.
    Lin YT; Wu BN; Wu JR; Lo YC; Chen LC; Chen IJ
    J Cardiovasc Pharmacol; 1996 Jul; 28(1):149-57. PubMed ID: 8797149
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.